Biotechnology Sector

In a groundbreaking study, researchers have unveiled a significant association between the monocyte-to-high-density lipoprotein (HDL) ratio, commonly referred to as MHR, and mortality rates among older individuals living with chronic kidney disease (CKD). This research, conducted by a team of experts including Gembillo, Soraci, and Luciani, sheds light on the multifaceted relationship between inflammation and

The intricate interplay of medication and elderly health has garnered significant attention in recent years, particularly in the context of anticholinergic drugs and their resultant burden on older patients. The phenomenon of anticholinergic burden refers to the cumulative effect of medications that block the action of acetylcholine, a neurotransmitter involved in many bodily functions. High

In an evolving healthcare landscape, the optimization of nursing resources in Post-Anesthesia Care Units (PACUs) has emerged as a pivotal concern for healthcare administrators. The efficient management of nursing personnel can significantly enhance patient outcomes, expedite recovery times, and improve overall service delivery. A recent study conducted by Xiong et al. sheds light on the

The use of face masks has become prevalent in recent years, primarily due to the global health crisis brought on by the COVID-19 pandemic. With the requirement for mask-wearing during public engagements, the necessity for accurate face mask detection technologies has surged. Researchers have directed their efforts toward developing methods that can enhance the performance

In a groundbreaking study, researchers led by Song et al. delve into the intricate world of rabbit meat quality, investigating how myofiber composition evolves throughout growth stages. The team meticulously analyzed the variations in myofiber types as rabbits mature, revealing significant implications for the meat production industry. The research, set to be published in BMC

In a groundbreaking study, researchers led by Jeon, H., Joo, Y., and Husni, P. have unveiled a novel framework for the architecture-driven optimization of nanocarriers specifically designed for pH-responsive drug delivery. This research, published in the renowned journal “J. Pharm. Investig,” offers promising insights into enhancing targeted drug delivery systems, addressing significant challenges within the

In a groundbreaking stride within the realm of artificial intelligence and medical imaging, researchers Vandana, C. Sharma, and A. Srivastava, among others, have unveiled a significant advancement in the detection and analysis of monkeypox through their innovative model, MpoxSegNet. This deep learning framework has been meticulously designed for the multiclass segmentation and classification of monkeypox

In recent years, the escalating presence of microplastics in terrestrial environments has garnered significant scientific and societal attention. While much of the initial research focused on aquatic ecosystems, soils represent a vast and complex matrix that can harbor diverse microplastic contaminants. The difficulty in accurately extracting and identifying microplastics from these soil matrices poses one

In a groundbreaking study set to be published in 2026, researchers Orkaby, Segev, and Saban delve into a compelling intersection of healthcare and artificial intelligence, exploring how dialectically different entities—the human mind of dialysis nurses and the computational intellect of AI—approach clinical reasoning. This research holds the potential to redefine the future of patient care

In recent years, the topic of concussion and its aftermath has gained significant attention, especially regarding children and adolescents. A novel study conducted in Germany has thrown light on the concerning prevalence of post-concussion-like symptoms in this vulnerable demographic. As our understanding of pediatric health continues to evolve, this research highlights the urgent need for

In recent advancements in geriatric psychiatry, a pivotal study has emerged investigating the risk factors associated with falls among older adults suffering from depression, specifically those receiving treatment with bupropion. The research, part of the OPTIMUM Randomized Clinical Trial, delves into critical facets of how pharmacotherapy can interact with the physiological and psychological state of

Emerging research has recently shed light on the innovative uses of agricultural waste, particularly that derived from sesame (Sesamum indicum). This study delves into the potential of transforming such waste into valuable resources through the green synthesis of bioactive silver nanoparticles. The pressing need for eco-friendly methods in nanotechnology is being addressed, as researchers strive

In a groundbreaking recent study, researchers have revealed significant insights into the prognostic capabilities of calcium-related genes in lung adenocarcinoma (LUAD) patients. The investigation was spearheaded by a team that includes Wei, Liu, and Qin, alongside a cohort of contributors whose collective expertise spans various fields within cancer research and cellular biology. Their work sheds

In an era where personalized medicine intertwines with cutting-edge technology, the latest research showcases a groundbreaking approach to treating one of the most aggressive forms of breast cancer—triple-negative breast cancer (TNBC). This research proposes an innovative strategy using hybrid bioinspired nanovesicles, designed meticulously to target tumor endothelial cells. The discovery by Gui, Zhao, Liu, and

In a groundbreaking study published in the Journal of Ovarian Research, researchers have uncovered remarkable insights into the interplay between circadian rhythms and reproductive physiology in prepubertal and pubertal rabbits. The paper, authored by Zhu et al., delineates a fascinating exploration into how night-restricted feeding schedules can influence ovarian health, particularly focusing on the interleukin-17

A recent study led by researchers Yi, Fan, Chen, and colleagues has highlighted the critical link between leisure activity patterns and health vulnerabilities among older adults in China. The ambitious nationwide analysis focuses on stark urban-rural differences, drawing upon extensive data from the China Health and Retirement Longitudinal Study (CHARLS). This research sheds light on

In the vast landscape of organizational research, understanding the complex relationship between organizational climate and employee retention continues to be a critical focal point for enhancing operational efficiency, particularly within high-stakes environments such as emergency and accident centers. A compelling study conducted in Iran sheds light on these dynamics, specifically analyzing how an organization’s climate

In a groundbreaking study published in the esteemed journal Ionics, researchers Sridhar, Manikandan, and Gobi have unveiled an innovative approach to enhancing supercapacitor performance through the utilization of bio-waste-derived activated carbon integrated with a MnO₂/NiO nanocomposite. This research is significant as it not only tackles the growing demand for efficient energy storage systems but also

In a groundbreaking study, researchers have begun to unravel the complex interplay between solvation effects and the performance of dye-sensitized solar cells (DSSCs) employing dioctyl sulfosuccinate (DBSA)-functionalized zinc oxide (ZnO) photoanodes. The findings provide a comprehensive insight into how solvation impacts charge transport mechanics within these quasi-solid-state solar cells, leading to enhanced energy conversion efficiencies.

In recent years, there has been increasing attention on the prescription and use of antipsychotic medications among transition-age youth on the autism spectrum. This demographic presents unique challenges and opportunities for medical professionals, as understanding the interplay between autism and antipsychotic treatments is crucial to ensuring optimal outcomes. A recent study aims to shed light

Discover J&J’s pipeline strategy for 2026 as it it projects that its sales for the year will be between $100 billion and $101 billion. The post Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its lead rare disease asset for approval, contradicting the biotech’s claims that the candidate’s eventual rejection came as a shock.

Moderna Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. Meanwhile, the mRNA specialist is welcoming a new chief development officer in the form of David Berman, M.D., Ph.D.

Chugai Pharmaceutical has dropped its only clinical candidate that was developed with the aid of its artificial intelligence drug discovery tool but is not giving up on the technology as a method to power its pipeline moving forward.

Today, our guest is Dr. Clare Wareing, Founder and CEO of Cumulus Oncology, who joins us from Edinburgh. The post Building a smart oncology pipeline with Cumulus Oncology appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.

The ink was barely dry on AstraZeneca’s announcement of a landmark investment in its Chinese capabilities before the U.K.-based pharma agreed to pay more than $1 billion to one of its regional partners.

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.

Cardiff is churning its leadership team as the biotech advances its colorectal cancer candidate onvansertib toward late-stage clinical development. CEO Mark Erlander, Ph.D., and Chief Financial Officer James Levine are both stepping down from their roles, triggering a search for their permanent successors.

AI-fueled Formation Bio has inked another licensing deal for a China asset, this time picking up an oral small molecule designed to treat autoimmune disease in a deal worth up to $500 million biobucks.

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Roche has waved goodbye to an inflammation drug from Kiniksa—as well as the $100 million the pharma paid for the therapy.

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance its capabilities in areas including cell therapies and radioconjugates.

Sanofi is tight-lipped about the future of its underwhelming pact with Denali Therapeutics after the French pharma scrapped what appeared to be the final RIPK1 inhibitor from the deal.

With three Big Pharma collaborations already under its belt, Flagship Pioneering spinout Repertoire Immune Medicines has picked up one more—and its biggest yet—in a further validation of the company’s immune system decoding platform.

The BIA 2025 report has revealed that despite a decline investments, the U.K. biotech sector has shown resilience. The post U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

After announcing plans to go public at the top of the year, Eikon Therapeutics has now revealed the proceeds it hopes to pull in from its initial stock offering: $273.5 million.

As biopharma M&A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.

A brain tumor has prompted the FDA to put clinical holds on two Regenxbio gene therapies, including a candidate that is less than two weeks away from an approval decision. Regenxbio’s share price fell 32% to $9.16 in premarket trading.

Delve into Italy's biotech landscape with seven companies that are leading the charge in the European country. The post Seven Italian biotechs to know about in 2026  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium channel inhibitor in patients with acute kidney injury over a “safety concern.”

Boehringer Ingelheim has shared more phase 2 data on its kidney disease candidate apecotrep, shedding light on the decision to start a pivotal trial of the prospect last week.

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offerings by penning a pact with gene editing company Seamless Therapeutics.

Since launching one year ago with a hearty $300 million series A, Kardigan has been on a biotech speedrun.

If the pursuit of Metsera signaled Novo Nordisk was ready to pay top dollar for the right innovation, the aftermath has filled Tamara Darsow’s calendar with high-stakes screenings for new opportunities.

Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi potency. The post How the University of North Carolina at Chapel Hill is enhancing RNAi potency with its new technology appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The FDA is freeing Intellia’s CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the sister study.

Emerging sinusitis treatments include monoclonal antibodies to tackle the unmet medical needs of patients. The post A clearer path to relief: sinusitis treatments on the way  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff is driving deals. The post What does 2026 hold for the biotech industry?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. The post Top 5 trends that will drive biopharma in the next decade with Tim Opler appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Here are some of the diseases that scientists aim to tackle using CRISPR technology, testing its possibilities and limits as a medical tool. The post Could CRISPR really cure these diseases?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Find out whether we are closing in on a cure for hepatitis B - a virus affecting the liver that can cause acute and chronic disease. The post Hepatitis B: Are we edging closer to a cure? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to scale. The post From science to scale: building biotech companies via milestone leadership appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Delve into the increasingly dynamic landscape of ALS treatment development with ten companies advancing candidates in 2026. The post Curing ALS? Ten companies developing new treatments in 2026  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

UZEDY (risperidone) Teva Patent: 10,736,965 Expiration: Jan 12, 2025 See More … For more information on how DrugPatentWatch can help Source

In the fast-paced world of pharmaceuticals, negotiations play a pivotal role in shaping the industry’s landscape. From mergers and acquisitions Source

The Art of Pharmaceutical Negotiations: What You Need to Know As a professional in the pharmaceutical industry, you're likely no stranger to the complexities of negotiations. From securing lucrative deals with manufacturers to navigating the intricacie... Source

The Generic Drug Revolution: Setting the Stage Before we dive into the nitty-gritty, let’s take a moment to appreciate the Source

Revolutionizing Generic Drug Development: Lessons from the Pioneers As the pharmaceutical industry continues to evolve, the quest for innovative approaches to generic drug development has never been more pressing. With the cost of prescription medicati... Source

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. Source

Unlocking the Potential of Biosimilars: A Closer Look at Market Dynamics Across Patient Populations As the biosimilar market continues to grow, it's essential to understand the nuances of how these treatments interact with different patient populations... Source

Navigating the complex landscape of drug development and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Source

Navigating the Complex World of Contract Development and Manufacturing: Top Tips for Startups As a startup in the pharmaceutical industry, you're likely no stranger to navigating complex landscapes. From regulatory hurdles to clinical trials, every ste... Source

A robust patent strategy can make or break a company’s success. With billions of dollars invested in research and development, Source

Maximizing Your Pharmaceutical Company's Potential: A Proven Approach to Optimizing Your Drug Patent Strategy As a pharmaceutical executive, you understand the importance of protecting your company's intellectual property and staying ahead of the compe... Source

Generic drugs play a crucial role in providing affordable medication options to patients. However, many individuals still harbor misconceptions and Source

Breaking Down Barriers: Educating Patients About Generic Drugs As healthcare professionals, we've all been there - a patient comes to us with concerns about a new medication, only to reveal that they're hesitant to switch to a generic alternative. It's... Source

TRILIPIX (choline fenofibrate) Abbvie Patent: 7,259,186 Expiration: Jan 7, 2025 See More … For more information on how DrugPatentWatch can Source

The biopharmaceutical industry is witnessing unprecedented growth, with the Contract Development and Manufacturing Organization (CDMO) market expected to reach $289.64 Source

Unlock the Full Potential of Your CDMO Partnership As a pharmaceutical executive, you know that partnering with a Contract Development and Manufacturing Organization (CDMO) can be a game-changer for your business. But have you ever wondered how to ensu... Source

Is Vascepa Effective for Reducing Heart Disease Risk? Heart disease is a leading cause of death worldwide, and reducing... https://www.Drugchatter.com/chat/45909/is-vascepa-effective-for-reducing-heart-disease-risk/ Source

Unlock the Secrets to a Thriving Generic Drug Development Strategy As a seasoned professional in the pharmaceutical industry, you know that developing a successful generic drug is no easy feat. With the ever-changing landscape of patent laws, regulator... Source

The Unseen Heroes of Affordable Healthcare: The Power of Generics As we navigate the complexities of the healthcare system, it's easy to overlook the unsung heroes that make a significant difference in our lives: generic medicines. These affordable alt... Source

The Hidden Power of Effective Patent Management: Unlocking Your Pharmaceutical Business's Full Potential As a pharmaceutical professional, you're likely no stranger to the complex world of drug patents. With the average cost of developing a new medicat... Source

With significant growth in activities globally, our /local page has strained to keep up and simply is not a great representation of the the larger community. So we’re happy to unveil this alpha system at sphere.diybio.org. You can get involved in shaping it. Our aim with DIYbiosphere is to make it easier for the community … … Continue reading →